Combined rapid atrial flutter/fibrillation and recurrent ventricular tachycardia occurred in an 82 year old man with acute myocardial infarction. Both arrhythmias were promptly terminated by intravenous sotalol, suggesting another use for this unique drug in the absence of hypotension, heart block or cardiac failure.
Introduction
Combined rapid atrial flutter/fibrillation and recurrent ventricular tachycardia is uncommon after acute myocardial infarction but usually demands urgent treatment to maintain a satisfactory cardiac output and reduce myocardial oxygen demands. We describe the prompt termination of both arrhythmias and restoration of sinus rhythm following intravenous sotalol administration. Lignocaine 100 mg was given intravenously but rapid atrial fibrillation and paroxysmal ventricular tachycardia continued. Ten minutes later, sotalol 40 mg was given intravenously over 15 minutes resulting in slowing of the ventricular rate, shortening of the bursts of ventricular tachycardia, brief periods of triplets and couplets and sudden return to sinus rhythm 70 beats/minute, 10 minutes after sotalol administration ( Figure Ic) . Blood pressure fell to 130/ 70 mmHg and the chest pain disappeared. The electrocardiogram showed sinus rhythm, right bundle branch block, q waves in V 1-3 and symmetrical T wave inversion in VI-6, AVL. Subsequent cardiac enzymes confirmed myocardial infarction. The patient had no further episodes of atrial fibrillation or ventricular tachycardia, remained in sinus rhythm and was discharged to the ward 24 hours later on oral sotalol 80 mg/day.
Discussion
Few drugs are capable of controlling combined rapid atrial flutter/fibrillation and recurrent ventricular tachycardia simultaneously and treatment often necessitates therapy with more than one antiarrhythmic agent or electrical cardioversion. Intravenous amiodarone may be effective although its onset of action may be slow and is unpredictable.'"2 Flecainide has been shown to be capable of restoring sinus rhythm in patients with either atrial fibrillation or ventricular tachycardia (but not both) and may be a suitable alternative due to its speed of action.3 In our patient, intravenous sotalol was promptly effective in restoring sinus rhythm without adverse effects. The additional benefit of relief of chest pain is a well recognized feature of early a-blockade in acute myocardial infarction. 4 Sotalol is known to have Class III antiarrhythmic activity which lengthens cardiac action potential duration and prolongs the effective refractory period of all cardiac tissue including the atria.5 These effects combined with its a-blocking action are thought to be the basis of the unique antiarrhythmic properties of sotalol and the drug should be remembered as a possible therapeutic option for patients with combined atrial and ventricular tachyarrhythmias postmyocardial infarction in the absence of hypotension, heart block or cardiac failure. 
